Collectively, these cross-cancer findings verify mechanism-driven uptake, dose-dependent efficacy, and favorable tolerability, providing a strong biological foundation for adapting LAT1/ASCT2/xCT-targeted α-radiotherapeutics to NSCLC and guiding the translational strategies discussed below. This evidence concerns the gene SLC7A5 and non-small cell lung carcinoma.